Permanently Farnesylated Prelamin A, Progeria, and Atherosclerosis
- 17 July 2018
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 138 (3) , 283-286
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severityHuman Molecular Genetics, 2012
- Cardiovascular Pathology in Hutchinson-Gilford Progeria: Correlation With the Vascular Pathology of AgingArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Prelamin A Acts to Accelerate Smooth Muscle Cell Senescence and Is a Novel Biomarker of Human Vascular AgingCirculation, 2010
- Laminopathies and the long strange trip from basic cell biology to therapyJournal of Clinical Investigation, 2009
- A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutationJournal of Clinical Investigation, 2006
- Lamin A-Dependent Nuclear Defects in Human AgingScience, 2006
- A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of ProgeriaScience, 2006
- Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndromeNature, 2003
- Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase–deficient miceNature Genetics, 2002
- Mouse Models of AtherosclerosisScience, 1996